Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2022-05-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of multiple doses of itraconazole on
singledose tepotinib pharmacokinetics in healthy participants. Study details include:
Study Duration: up to 48 days Treatment Duration: single dose of tepotinib on Days 1 and 12,
11 days of treatment with itraconazole (Days 8 to 18) Visit Frequency: residence in the
Clinical Research Unit from Days -1 to 4 and Days 11 to 15, ambulatory daily visits from Days
5 to 10 and 16 to 20
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany